Clinical implications of normal B-type natriuretic peptide levels in patients with severe chronic heart failure

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992; 20:248-54.10.1016/0735-1097(92)90167-LOpen DOISearch in Google Scholar

2. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003; 24:1735-43.10.1016/j.ehj.2003.07.005Open DOISearch in Google Scholar

3. Rothenburger M, Wichter T, Schmid C, Stypmann J, Tjan TD, Berendes E. et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant. 2004; 23:1189-97.10.1016/j.healun.2004.07.006Open DOISearch in Google Scholar

4. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000; 102:3060-7.10.1161/01.CIR.102.25.3060Open DOISearch in Google Scholar

5. Ueland T, Kjekshus J, Fr∅land SS, Omland T, Squire IB, Gullestad L, et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol. 2005; 46:2018-2021.10.1016/j.jacc.2005.08.039Open DOISearch in Google Scholar

6. Merz WM, Kubler K, Albers E, Stoffel-Wagner B, Gembruch U. N-terminal pro-B-type natriuretic peptide in the circulation of fetuses with cardiac malformations. Clin Res Cardiol. 2012; 101:73-9.10.1007/s00392-011-0366-4Open DOISearch in Google Scholar

7. Solheim E, Off MK, Hoff PI, De Bortoli A, Schuster P, Ohm OJ, et al. N-terminal pro-B-type natriuretic peptide level at long-term follow-up after atrial fibrillation ablation: a marker of reverse atrial remodelling and successful ablation. J Interv Card Electrophysiol. 2012; 34:129-36.10.1007/s10840-011-9629-2Search in Google Scholar

8. McGeoch G, Lainchbury J, Town GI, Toop L, Espiner E, Richards AM. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail, 2002; 4:479-83.10.1016/S1388-9842(02)00027-2Open DOISearch in Google Scholar

9. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation, 2003; 16:2964-6.10.1161/01.CIR.0000106903.98196.B6Open DOISearch in Google Scholar

10. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362:316-22.10.1016/S0140-6736(03)13976-1Open DOISearch in Google Scholar

11. Hall C Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail. 2004; 6:257-610.1016/j.ejheart.2003.12.01514987573Open DOISearch in Google Scholar

12. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma Nterminal probrain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998; 97:1921-9.10.1161/01.CIR.97.19.1921Open DOISearch in Google Scholar

13. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93:1963-9.10.1161/01.CIR.93.11.1963Open DOISearch in Google Scholar

14. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem. 2004; 50: 33-50.10.1373/clinchem.2003.02476014633912Open DOISearch in Google Scholar

15. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest. 2001; 61:33-42.10.1080/0036551015106794711300609Open DOISearch in Google Scholar

16. Vanderheyden M, Vrints C, Verstreken S, Bartunek J, Beunk J, Goethals M. B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications. Biomark Med, 2010; 4:315-20.10.2217/bmm.10.520406072Open DOISearch in Google Scholar

17. Mohammed SF, Korinek J, Chen HH, Burnett JC, Redfield MM. Nesiritide in acute decompensated heart failure: current status and future perspectives. Circ Heart Fail. 2008; 1:258-64.Search in Google Scholar

18. Miller WL, Burnett JC Jr, Hartman KA, Henle MP, Burritt MF, Jaffe AS. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in severe heart failure patients treated with nesiritide. Am J Cardiol, 2005; 15: 837-41.10.1016/j.amjcard.2005.05.03216169373Open DOISearch in Google Scholar

19. Sun T, Wang L, Zhang Y. Prognostic value of B-type natriuretic peptide in patients with chronic and advanced heart failure. Intern Med J, 2007, 37:168-171.10.1111/j.1445-5994.2006.01296.x17316335Open DOISearch in Google Scholar

20. Niederkofler EE, Kiernan UA, O’Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008; 1: 258-64.10.1161/CIRCHEARTFAILURE.108.79077419808300Search in Google Scholar

21. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol. 2009; 53:2343-8.10.1016/j.jacc.2009.02.05819539144Open DOISearch in Google Scholar

22. Smith DT, Farzaneh-Far R, Ali S, Na B, Whooley MA, Schiller NB. Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction. Am J Cardiol, 2010; 105:223-8.10.1016/j.amjcard.2009.08.677282730820102923Open DOISearch in Google Scholar

23. Earl GL, Verbos-Kazanas MA, Fitzpatrick JM, Narula J. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. Pharmacotherapy. 2007; 27:697-706.10.1592/phco.27.5.69717461705Open DOISearch in Google Scholar

24. Yang ZY, Li KL, Wang Q, Wang RX. Clinical characteristics of severe chronic heart failure patients with normal blood B-type natriuretic peptide. Chin J Cariol, 2010; 38:979-982 (in Chinese). Search in Google Scholar